Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
FRX [NYSE]
Forest Laboratories Inc.
IndexS&P 500 P/E154.45 EPS (ttm)0.58 Insider Own0.50% Shs Outstand270.96M Perf Week2.51%
Market Cap24.27B Forward P/E24.54 EPS next Y3.65 Insider Trans-29.80% Shs Float269.42M Perf Month-6.69%
Income156.70M PEG2.38 EPS next Q0.43 Inst Own91.40% Short Float1.20% Perf Quarter31.20%
Sales3.37B P/S7.21 EPS this Y-103.40% Inst Trans-0.07% Short Ratio0.85 Perf Half Y102.90%
Book/sh22.24 P/B4.03 EPS next Y176.17% ROA2.00% Target Price82.00 Perf Year152.77%
Cash/sh11.16 P/C8.03 EPS next 5Y65.00% ROE2.70% 52W Range35.22 - 100.88 Perf YTD49.23%
Dividend- P/FCF100.55 EPS past 5Y-15.30% ROI-1.10% 52W High-11.20% Beta0.83
Dividend %- Quick Ratio3.70 Sales past 5Y-3.60% Gross Margin79.50% 52W Low154.34% ATR2.61
Employees5800 Current Ratio4.10 Sales Q/Q22.60% Oper. Margin6.20% RSI (14)46.22 Volatility2.67% 2.91%
OptionableYes Debt/Eq0.20 EPS Q/Q112.10% Profit Margin4.70% Rel Volume0.29 Prev Close90.29
ShortableYes LT Debt/Eq0.20 EarningsApr 29 BMO Payout0.00% Avg Volume3.82M Price89.58
Recom2.60 SMA20-1.24% SMA50-0.10% SMA20049.83% Volume1,095,921 Change-0.79%
19-Feb-14Reiterated Barclays Equal Weight $74 → $90
19-Feb-14Downgrade Mizuho Buy → Neutral $93
19-Feb-14Downgrade CRT Capital Buy → Fair Value $78 → $93
14-Jan-14Reiterated Argus Buy $62 → $77
09-Jan-14Reiterated UBS Neutral $57 → $72
09-Jan-14Reiterated Mizuho Buy $70 → $90
09-Jan-14Reiterated CRT Capital Buy $63 → $78
11-Dec-13Reiterated Argus Buy $62
03-Dec-13Reiterated UBS Neutral $47 → $57
03-Dec-13Reiterated FBR Capital Outperform $59 → $70
03-Dec-13Reiterated Barclays Equal Weight $39 → $50
22-Nov-13Reiterated Mizuho Buy $50 → $59
30-Oct-13Initiated FBR Capital Mkt Perform $48
23-Oct-13Reiterated Barclays Equal Weight $36 → $39
24-Jul-13Reiterated Cantor Fitzgerald Buy $52 → $56
09-Jul-13Reiterated Mizuho Buy $44 → $49
13-Jun-13Reiterated Cantor Fitzgerald Buy $45 → $48
05-Jun-13Upgrade Argus Hold → Buy $46
18-Apr-13Reiterated Cantor Fitzgerald Buy $48 → $45
16-Jan-13Reiterated Deutsche Bank Hold $34 → $36
17-Apr-14 04:33PM  [$$] Actavis, Forest Labs Get Second FTC Request for Merger Info at The Wall Street Journal
04:05PM  Actavis and Forest Laboratories Receive FTC Second Request Under Hart-Scott-Rodino PR Newswire
04:05PM  Actavis and Forest Laboratories Receive FTC Second Request Under Hart-Scott-Rodino Business Wire
10-Apr-14 04:02PM  Biotech IPOs Adamas, Cerulean Slump In Trading Debut at Investor's Business Daily
03:40PM  Regulatory Update from Forest Labs Zacks
12:44PM  [video] Icahn: eBay could be another Netflix at CNBC
12:40PM  [video] Icahn: eBay very undervalued at CNBC
12:37PM  [video] Icahn eased feelings about eBay CEO at CNBC
12:34PM  [video] Icahn: eBay's Donahoe has passion, company has potential at CNBC
08:30AM  Ironwood and Forest Launch New Direct-to-Consumer Awareness Campaign For LINZESS® Business Wire
08:00AM  Ironwood and Forest Launch New Direct-to-Consumer Awareness Campaign For LINZESS® Business Wire
12:27AM  Buy Actavis - An Attractive Value And Growth Play That Is Also A Top Guru Fund Pick at Seeking Alpha
09-Apr-14 03:17AM  Forest Laboratories and Almirall Provide Update on the Fixed Dose Combination of Aclidinium and Formoterol in the U.S. Business Wire
04-Apr-14 05:28PM  Mylan Bid Gets Rejected, But Generic-Drugmaker Rises at Investor's Business Daily
04:00PM  Merck KGaA and Auxogyn Collaborate Zacks
12:27PM  Mylan Rejected In Bid To Acquire Sweden's Meda at Investor's Business Daily
09:17AM  The Zacks Analyst Blog Highlights: China Southern Airlines, China Petroleum and Chemical, Baidu, Actavis and Forest Laboratories Zacks
01-Apr-14 04:40PM  Positive Data on Forest Labs/Gedeon's Cariprazine Zacks
08:01AM  Stocks looking up to start the second quarter; Another GM recall as CEO prepares to testify; Caterpillar avoided $2.4 billion in taxes: Senate report Hot Stock Minute
08:00AM  Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2014 Fourth Quarter Earnings Business Wire
31-Mar-14 04:00PM  [video] Q1 wrap-up: Big winners at CNBC
03:21PM  Why Forest Labs, Nabors Industries, and Keurig Green Mountain Have Led the S&P Higher This Quarter at Motley Fool
07:48AM  Early movers: LULU, GM, TSLA, C, AAPL, BBRY & more at CNBC
03:00AM  Forest Laboratories, Inc. and Gedeon Richter Plc. Announce Positive Phase IIb Topline Results for Cariprazine for the Treatment of Bipolar Depression Business Wire
02:26AM  Cariprazine positive for bipolar patients - Forest, Richter Reuters
27-Mar-14 01:15PM  Dealpolitik: U.S. Taxpayers' Big Contribution to the Actavis-Forest Labs Deal at The Wall Street Journal
21-Mar-14 03:00AM  Forest Laboratories, Inc. and Gedeon Richter Plc. Announce Positive Phase IIb Topline Results for Cariprazine as Adjunctive Therapy in the Treatment of Major Depressive Disorder Business Wire
19-Mar-14 03:45PM  New Data on Pacira's Exparel Zacks
02:00PM  Fetal-Brain Protein Sparks in Old Age to Fight Dementia at Bloomberg
18-Mar-14 07:29PM  Forest Laboratories' Recovery Gurufocus
07:29PM  Forest Laboratories' Recovery
08:58AM  Update-Moody's assigns a first time Ba3 CFR to Almirall; outlook stable Reuters
17-Mar-14 06:35PM  Shorts Are Piling Into These Stocks. Should You Be Worried? at Motley Fool
08:09AM  A Wall Street Transcript Interview with Matt Miksic, a Managing Director and Senior Research Analyst at Piper Jaffray & Co., Covering Medical Technology and Hospital Supply Stocks: Improved Volumes, Uptick in M&A Activity Across Medical Dev Wall Street Transcript
14-Mar-14 11:56AM  [$$] Picks to Play the New Antibiotics Bill at Barrons.com
11:56AM  [$$] Picks to Play the New Antibiotics Bill
07-Mar-14 09:30AM  Merck KGaA Misses 2013 Earnings & Rev Ests Zacks
06-Mar-14 12:02PM  3 Drugs Stocks Dragging The Industry Down at TheStreet
10:43AM  Icahn Fires Again In EBay Fight, Targets Andreessen And PayPal Split at Forbes
10:43AM  Icahn Fires Again In EBay Fight, But Where's The PayPal Plan? at Forbes
10:43AM  Icahn Fires Again In Ebay Fight, But Where's The PayPal Plan? at Forbes
05-Mar-14 12:21PM  Investor Alert: Pittsburgh Law Office of Alfred G. Yates, Jr., P.C. Announces Investigations into Carnival Corporation (NYSE: CCL), Emeritus Corp. (ESC), FedEx Corporation (FDX), Forest Laboratories (FRX), Immunomedics (IMMU), JPMorgan Chas PR Newswire
04-Mar-14 06:21PM  Precious Metals, Health Care Led Mutual Funds In Feb. Optionetics
06:21PM  Precious Metals, Health Care Led Mutual Funds In Feb. at Investor's Business Daily
06:21PM  Precious Metals, Health Care Led Mutual Funds In Feb.
05:31PM  Forest Labs Submits NDA for Alzheimer's Drug Combination at Motley Fool
05:13PM  Drugmakers Actavis, Biogen, Valeant Hold Near Highs Optionetics
05:13PM  Drugmakers Actavis, Biogen, Valeant Hold Near Highs at Investor's Business Daily
05:13PM  Drugmakers Actavis, Biogen, Valeant Hold Near Highs
04:20PM  Forest Labs Seeks Bystolic-Diovan Approval Zacks
04:20PM  Forest Labs Seeks Bystolic-Diovan Approval
08:00AM  Forest Laboratories and Adamas Pharmaceuticals Announce Forests Submission of New Drug Application for Memantine Extended Release and Donepezil Fixed-Dose Combination for Alzheimers Disease Business Wire
08:00AM  Forest Laboratories and Adamas Pharmaceuticals Announce Forests Submission of New Drug Application for Memantine Extended Release and Donepezil Fixed-Dose Combination for Alzheimers Disease
03-Mar-14 10:22AM  Icahn Enterprises reports profit up 144% in 2013 at MarketWatch
02-Mar-14 11:31AM  The Biggest S&P Winners So Far in 2014 at Motley Fool
27-Feb-14 12:04PM  Mylan soars to 52-week high after saying 'poised' for transaction at theflyonthewall.com
12:04PM  Mylan soars to 52-week high after saying 'poised' for transaction
08:03AM  Forest Labs submits NDA for Nebivolol and Valsartan combination in hypertension theflyonthewall.com
08:00AM  Forest Laboratories Submits a New Drug Application for Nebivolol and Valsartan Combination in Hypertension Business Wire
25-Feb-14 04:34PM  Follow The Money: Defensive Stocks On The Move at Seeking Alpha
24-Feb-14 08:00AM  Forest Laboratories, Inc. Launches STRIDE Patient Support Program for COPD Franchise Products Tudorza® Pressair® and Daliresp® Business Wire
06:09AM  Forest Labs downgraded to Neutral from Outperform at Credit Suisse at theflyonthewall.com
05:31AM  U.S. stock market is starting to ride a tech M&A wave at MarketWatch
03:28AM  Greed Turning Losers to Leaders in Russell 1000 Index Bloomberg
22-Feb-14 08:25AM  3 Humongous Health-Care Stocks This Week at Motley Fool
02:32AM  [$$] Last Week at Barrons.com
21-Feb-14 02:31PM  Here's What You Need to Know About Actavis plc's Acquisition of Forest Labs at Motley Fool
02:02PM  Forest Laboratories Sued by Investor Over Actavis Buy at Bloomberg
11:22AM  Law Firm Brower Piven Announces Investigation of Forest Laboratories, Inc. Proposed Buyout Business Wire
20-Feb-14 02:20PM  Why 2014 could be the year of the megamerger at CNBC
02:04PM  Smart Money sells into Mylan rise for a good reason at MarketWatch
11:21AM  Actavis Q4 Beats Street; Guidance Affirmed For Now at Investor's Business Daily
10:25AM  Forest Oil Trying To Make A Go Of It With Second-Rate Assets at Seeking Alpha
05:57AM  Can Shire (SHPG) Continue to Surge? Zacks
19-Feb-14 06:07PM  Medicals Among Top 20 Groups, Retailers Near Bottom at Investor's Business Daily
05:32PM  FOREST LABORATORIES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Business Wire
05:19PM  FOREST LABORATORIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princi EDGAR Online
05:18PM  Is It Too Soon To Call 2014 A Year Of Mergers And Acquisitions? at TheStreet
04:57PM  Stocks close near session lows, Nasdaq snaps 8-day win streak at CNBC
02:45PM  Top-Ranked Forest Labs Soars on Buyout News Zacks
02:16PM  Stocks stutter-step after Fed minutes; nat gas hits 5-year high at CNBC
12:31PM  INVESTOR ALERT: LEVI & KORSINSKY, LLP Announces Investigation of FOREST LABORATORIES, INC. and Its Board of Directors In Connection With the Sale of the Company to Actavis plc Business Wire
12:20PM  Stocks turn lower in choppy session ahead of Fed minutes at CNBC
12:07PM  Actavis: Caterpillar Becoming Butterfly; Time to Buy, Goldman Sachs Says at Barrons.com
11:54AM  [video] Forest Labs, Ashland Roll Up Big Post-Holiday Deals at TheStreet
11:40AM  Finkelstein Thompson LLP Investigates Potentially Unfair Buyout of Forest Laboratories, Inc. Business Wire
11:12AM  Dow, S&P higher ahead of Fed minutes; FB hits all-time high at CNBC
11:03AM  Actavis, Forest shares continue their climb in aftermath of $25 billion deal at MarketWatch
10:04AM  Actavis-Forest Bid Shines Light on Valeant Next: Real M&A at Bloomberg
09:54AM  Forest Laboratories, Inc. Stockholders Encouraged to Contact Securities Law Firm about Takeover PR Newswire
09:51AM  Stocks flat ahead of Fed minutes; Facebook hits all-time high at CNBC
09:27AM  Stock Downgrades: The Sun'll Come Out Tomorrow for SolarCity, but Today Its Stock Isn't for Orphans at Minyanville
09:27AM  Stock Downgrades: SolarCity, Dollar General, and Forest Labs at Minyanville
08:28AM  Actavis price target raised to $250 on Forest Labs deal at Buckingham theflyonthewall.com
06:09AM  Forest Labs downgraded by Mizuho and CRT Capital Briefing.com
06:01AM  Coca-Cola Falls, Forest Labs Gets Bought As Dow Falls at Motley Fool
05:38AM  Actavis expected to seek more deals, WSJ reports at theflyonthewall.com
12:01AM  Icahns Fight Opened Door to Actavis Move Past Generics at Bloomberg
18-Feb-14 10:35PM  Biotech Continues to Lead Market: Innovation and M&A at TheStreet +27.52%
09:02PM  Acquisition of Forest Laboratories, Inc. by Actavis plc May Not Be in Shareholders' Best Interests PR Newswire
Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe. The company's products include Linzess for the treatment of irritable bowel syndrome with constipation or chronic idiopathic constipation; Tudorza Pressair, an antimuscarinic agent to treat bronchospasm associated with chronic obstructive pulmonary disease; Viibryd for the treatment of adults with major depressive disorder (MDD); and Daliresp, a phosphodiesterase-4 enzyme inhibitor to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD. Its products also comprise Teflaro for the treatment of adults with skin and skin structure infections; Bystolic to treat hypertension; Namenda and Namenda XR for the treatment of moderate and severe Alzheimer's disease; Savella to treat fibromyalgia; and Colobreathe, a dry powder inhaler for the treatment of chronic lung infections. In addition, the company develops Levomilnacipran, which is under Phase III clinical trials for the treatment of MDD; Cariprazine that is in Phase III clinical trials to treat acute exacerbation of schizophrenia and acute mania associated with bipolar disorder; ceftazidime/avibactam, which is under Phase III clinical trials for intra-abdominal infections and for complicated urinary tract infections; and Cebranopadol (GRT 6005) that has completed Phase II clinical trials for moderate to severe chronic pain conditions. Forest Laboratories, Inc. sells its products directly to physicians, pharmacies, hospitals, managed care, and other healthcare organizations, as well as through independent distributors. It has collaborative licensing option agreement with Trevena for the development of TRV027 for the treatment of acute decompensated heart failure; and collaboration agreement with Ironwood develop and commercialize Linzess. The company was founded in 1956 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Forest Laboratories Holdings L10% OwnerFeb 05Buy7.00428,5712,999,9973,393,466Feb 07 01:14 PM
SOLOMON HOWARDDirectorJan 27Sale64.3221,7441,398,641464,881Jan 27 04:52 PM
SOLOMON HOWARDDirectorJan 24Sale65.51228,25614,952,892486,625Jan 27 04:52 PM
SOLOMON HOWARDDirectorJan 23Sale67.13250,00016,782,500714,881Jan 24 05:08 PM
Lynch JeromeSVP-SalesJan 22Option Exercise35.80135,6254,855,924202,202Jan 24 04:58 PM
Lynch JeromeSVP-SalesJan 22Sale67.28135,6259,124,19966,577Jan 24 04:58 PM
OLANOFF LAWRENCE SDirectorAug 26Sale42.961,10447,43191,354Aug 27 03:23 PM
Francis Perier I JrEVP Finance & Admin. & CFOAug 21Sale43.0012,000516,00099,439Aug 23 11:07 AM